CHENGDU, China, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Inc., (OTC Bulletin Board: VSCO), a manufacturer and supplier of modernized traditional Chinese medicine (TCM) based in Chengdu, China, today announced that Mr. Stewart Lor, a member of the Board of Directors, will host a conference call to update shareholders on the 2008 second quarter financial results.
The conference call will take place at 4:15 p.m. EST, on Thursday, February 14th, 2008. Interested participants should call 800-762-8908 within the United States, or US + 1-480-629-1990 if calling internationally. It is advisable to dial in approximately 5-10 minutes prior to 4:15 p.m. EST. There will be a playback available until March 15, 2008. To listen to the playback, please call 800-406-7325 from within the United States, or US +1 303-590-3030 internationally. Please use pass code 3843464 for the replay.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 869 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
|SOURCE Tianyin Pharmaceutical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved